Search by Journal

The Japanese Society of Psychiatric Pharmacy

Volume , Issue suppl / 2024
English Article   Japanese Article
  • Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Japanese Article It is ... greetings to the eighth Japanese mental Pharmaceutical Society general meeting, psychiatry medicine medicine cooperation - Here we go to make for academic meeting infinite possibility, Next Stage
黒沢雅広
The Japanese Society of Psychiatric Pharmacy (suppl): 3-3, 2024.
Japanese Article PL. What is what ... psychiatrist really demands from a pharmacist from the questionary survey about the role of the hospital pharmacist for the improvement in quality of the psychiatry medical therapy? ...
黒沢雅広
The Japanese Society of Psychiatric Pharmacy (suppl): 38-38, 2024.
Japanese Article EL1. The mental disorder that we examined from the bowels
真田建史1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 39-39, 2024.
Japanese Article EL2. We know the antipsychotics: Treatment objective disease and how to use
松崎朝樹
The Japanese Society of Psychiatric Pharmacy (suppl): 40-40, 2024.
Japanese Article EL3. The actual situation of commercial drug abuse, the dependence judging from drug addiction clinical practice and remedial problem
松本俊彦
The Japanese Society of Psychiatric Pharmacy (suppl): 41-41, 2024.
Japanese Article Symposium 1. Term of the medical offer Chairman in disaster settings
鈴木弘道, 岩澤恭介
The Japanese Society of Psychiatric Pharmacy (suppl): 42-42, 2024.
Japanese Article SY1-1. Role of a summary and the physician of the disaster psychiatric care
高橋晶1,2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 43-43, 2024.
Japanese Article SY1-2. It is ... from the position of activity ... nurse of DPAT in the Noto Peninsula earthquake
石田正人
The Japanese Society of Psychiatric Pharmacy (suppl): 44-44, 2024.
Japanese Article SY1-3. Role of the pharmacist in the DPAT activity
辛島昌秀
The Japanese Society of Psychiatric Pharmacy (suppl): 45-45, 2024.
Japanese Article SY1-4. About the activity as the disaster support pharmacist in the Great East Japan Earthquake, Kumamoto earthquake and the Noto Peninsula earthquake and operation of mobile pharmacy (MP)
松本有右1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 46-46, 2024.
Japanese Article Symposium 2. It is a term of ... Chairman in attentive ears with introduction to cooperation practice - professor of "mental disorder X body complications" in Bar Prova
三輪高市, 中村友喜, 別所千枝
The Japanese Society of Psychiatric Pharmacy (suppl): 47-47, 2024.
Japanese Article SY2-1. Electrolyte abnormality and QT prolonged in the mental disorder X cardiovascular disease
高井靖
The Japanese Society of Psychiatric Pharmacy (suppl): 48-48, 2024.
Japanese Article SY2-2. From the intervention example of the cooperation psychiatry pharmacist in the mental disorder X perinatal period
小池眞菜美
The Japanese Society of Psychiatric Pharmacy (suppl): 49-49, 2024.
Japanese Article SY2-3. Efforts to cooperation of "mental disorder X body complications" in the acute phase hospital
田上浩子, 田中惇一, 宮崎俊明, 筒井由佳
The Japanese Society of Psychiatric Pharmacy (suppl): 50-50, 2024.
Japanese Article Symposium 3. What is necessary to make medicine medicine, medicine cooperation in the psychiatric practice better? Term of the Chairman
黒沢雅広, 中田裕介
The Japanese Society of Psychiatric Pharmacy (suppl): 51-51, 2024.
Japanese Article SY3-1. The current situation and the future of the medicine medicine cooperation in the psychiatric practice that we saw from a drugstore pharmacist
窪寺雅
The Japanese Society of Psychiatric Pharmacy (suppl): 52-52, 2024.
Japanese Article SY3-2. In an ideal and real interval
伊藤香織
The Japanese Society of Psychiatric Pharmacy (suppl): 53-53, 2024.
Japanese Article SY3-3. With medicine medicine, the pharmaceutical cooperation in the psychiatric practice?
新村一樹
The Japanese Society of Psychiatric Pharmacy (suppl): 54-54, 2024.
Japanese Article SY3-4. From a situation of thing - Ministry of Health, Labour and Welfare expecting about medicine medicine cooperation in the psychiatric practice, a pharmacist and the cooperation with the psychiatrist ...
竹野伸洋
The Japanese Society of Psychiatric Pharmacy (suppl): 55-55, 2024.
Japanese Article Symposium 4. Term of SDM and the multi-type of job cooperation Chairman in Japanese Society of Sleep Research, mental Pharmaceutical Society combination symposium insomnia treatment in Japan
内村直尚, 黒沢雅広
The Japanese Society of Psychiatric Pharmacy (suppl): 56-56, 2024.
Japanese Article SY4-1. Analysis of prescription status aiming at appropriate use of sleep medications at Karasuyama Hospital - Preliminary survey for introduction of Showa University formulary -
細川琴実
The Japanese Society of Psychiatric Pharmacy (suppl): 57-57, 2024.
Japanese Article SY4-2. Efforts ... from a medical safe report in inside the hospital to effect - fall fall preventive measures of the sleeping drug which we saw
坂内めぐみ
The Japanese Society of Psychiatric Pharmacy (suppl): 58-58, 2024.
Japanese Article SY4-3. Use of Decision Aid and Decision Coaching in Treating Insomnia
青木裕見
The Japanese Society of Psychiatric Pharmacy (suppl): 59-59, 2024.
Japanese Article SY4-4. SDM and the multi-type of job cooperation in insomnia treatment that a physician expects
高江洲義和
The Japanese Society of Psychiatric Pharmacy (suppl): 60-60, 2024.
Japanese Article Symposium 5. Considering the role of insurance pharmacies in "Regional Comprehensive Care System that also caters to patients with mental illness" - Possibilities for regional collaboration using information sharing tools - Chairman's words
竹内尚子, 有山智博
The Japanese Society of Psychiatric Pharmacy (suppl): 61-61, 2024.
Japanese Article SY5-1. Creating value for insurance pharmacies in "Regional Comprehensive Care System that also caters to patients with mental illness" - Through drug-drug collaboration and contributions to local medical care -
近藤浩樹1), 上條千恵子1), 崔友子1), 倉岡徹1), ジョーンズ千絵1), 羽佐田祥浩2), 和田智仁2), 三輪歌織2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 62-62, 2024.
Japanese Article SY5-2. From position of efforts - hospital pharmacist of the regional alliances utilizing the information sharing tool -
和田智仁
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2024.
Japanese Article SY5-3. Cooperation with the multi-type of job utilizing the tracing report
福田和博
The Japanese Society of Psychiatric Pharmacy (suppl): 64-64, 2024.
Japanese Article SY5-4. Regarding the results of the survey on "Regional Comprehensive Care System that also caters to patients with mental illness" conducted by the Regional Medical Cooperation Promotion Committee of our association
北口大介
The Japanese Society of Psychiatric Pharmacy (suppl): 65-65, 2024.
Japanese Article WS1. We will study the study associated with the mental pharmacy
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 66-66, 2024.
Japanese Article WS2. EGUIDE project workshop for pharmacists
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 67-67, 2024.
Japanese Article WS3. Medicine Hara-related extrapyramidal symptoms measure (DIEPSS) training
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 68-68, 2024.
Japanese Article By psychiatric practice as a pharmacist is ... from viewpoints such as ... EBM, clinical studies, the psychology, and the like to think, "is useful" of patients
細川智成
The Japanese Society of Psychiatric Pharmacy (suppl): 69-69, 2024.
Japanese Article 1 case of treatment-resistant schizophrenia that resulted in rhabdomyolysis during Clozapine treatment
丸山智大
The Japanese Society of Psychiatric Pharmacy (suppl): 70-70, 2024.
Japanese Article LS1-1. Treatment strategy in consideration of distribution, PK/PD to a target organ
井上悟
The Japanese Society of Psychiatric Pharmacy (suppl): 71-71, 2024.
Japanese Article LS1-2. Considerations from experience with acute schizophrenia : How to use LONASEN Tapes
出川えりか
The Japanese Society of Psychiatric Pharmacy (suppl): 72-72, 2024.
Japanese Article LS2. You think, and how do you evaluate "anxiety-related pain" associated with the depression how?
櫻井準
The Japanese Society of Psychiatric Pharmacy (suppl): 73-73, 2024.
Japanese Article LS3. Insomnia treatment strategy in the psychiatry practice
天神雄也
The Japanese Society of Psychiatric Pharmacy (suppl): 74-74, 2024.
Japanese Article LS4. ... to regard as the teachers of the pharmacist about insomnia treatment strategy - drug, nonpharmacologic therapy that fixed its eyes on an exit in the future
内村直尚
The Japanese Society of Psychiatric Pharmacy (suppl): 75-75, 2024.
Japanese Article LS5. About tardive dyskinesia and JIS British antilewisite
稲田健
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2024.
Japanese Article LS6-1. The role of pharmacists in task shifting
眞野成康
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2024.
Japanese Article LS6-2. Task shifting in the psychiatric field - What is the role of pharmacists? -
谷藤弘淳
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2024.
Japanese Article MS-1. ... which founds possibility for treatment of role - schizophrenia of LAI
佐藤誠
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2024.
Japanese Article MS-2. About the multi-type of job cooperation LAI introduction program pharmacist-led for LAI treatment promotion
辛島昌秀
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2024.
Japanese Article O1-1. Development of the cognitive function rating system that considered promotion of the social participation in patients with schizophrenia
清水侑真1), 三浦直緒2), 竹内一平2,3), 波多野正和2,4), 半谷眞七子1,2), 藤田潔3), 岩田仲生5), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 82-82, 2024.
Japanese Article O1-2. Additional investigation about the search of the risk factor about the leukopenia derived from Clozapine
佐藤雅也1), 藤田康平2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 82-82, 2024.
Japanese Article O1-3. One case that a pharmacist intervened in TDM in the low-dose continuous administration of the Clozapine
藤江直輝1), 青木涼1), 瀬川翼1), 原田学1), 下村好子1), 岩崎理一2), 四方佳美1)
The Japanese Society of Psychiatric Pharmacy (suppl): 83-83, 2024.
Japanese Article O1-4. 2 cases that showed improvement of the tardive dyskinesia by strange medicine to blonanserin tape preparation
小山健斗1), 柘野佑太2), 堤祐一郎2)
The Japanese Society of Psychiatric Pharmacy (suppl): 83-83, 2024.
Japanese Article O1-5. Look at the rear about the usefulness of the blonanserin patch in the delirium treatment and the safety; a mark investigation
鈴木田万里1), 重面雄紀1), 平大樹1), 谷向仁2), 川島啓嗣3), 須賀原教子4), 圓東寛基1), 山口拓真1), 北田徳昭1), 幾田慧子1), 勝部友理恵1), 今吉菜月1), 中川俊作1), 津田真弘1,5), 寺田智祐1)
The Japanese Society of Psychiatric Pharmacy (suppl): 84-84, 2024.
Japanese Article O2-1. Early cancellation of guanfacine for an attention defect, the hyperactivity disorder and somnolent association
祖川倫太郎1), 土井絹華1), 江口祐子2), 松尾宗明3), 島ノ江千里1)
The Japanese Society of Psychiatric Pharmacy (suppl): 84-84, 2024.
Japanese Article O2-2. Examination of the risk factor of the current situation and the constipation of the bowel movement situation of the inpatient
小林真美1), 馬場真佐美2), 小澤篤詞3)
The Japanese Society of Psychiatric Pharmacy (suppl): 85-85, 2024.
Japanese Article O2-3. Examination about the association between adverse event frequency and renal function of the paliperidone preparation
青木涼, 藤江直輝, 瀬川翼, 原田学, 下村好子, 四方佳美
The Japanese Society of Psychiatric Pharmacy (suppl): 85-85, 2024.
Japanese Article O2-4. The association between sexual dysfunction and receptor with antipsychotics: a pharmacovigilance-pharmacodynamic approach
堀井里奈1,2), 波多野正和1,2), 山田成樹1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 86-86, 2024.
Japanese Article O2-5. Acceptability evaluation of lemborexant and suvorexant : An inverse probability of treatment weighting analysis
羽田野光汰1,2), 荒木遥菜1,2), 波多野正和1,2), 山田成樹1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 86-86, 2024.
Japanese Article O3-1. Patient's share of medical expenses investigation of the medical treatment in patients with bipolar disorder
小林史弥1), 榊原崇1), 半谷眞七子2), 亀井浩行2)
The Japanese Society of Psychiatric Pharmacy (suppl): 87-87, 2024.
Japanese Article O3-2. Examination about the effect that the symptom disease severity of the child developmental disease gives to the mental health state of the parent
武内美喜子1), 柴田勲2)
The Japanese Society of Psychiatric Pharmacy (suppl): 87-87, 2024.
Japanese Article O3-3. Examination of the effect of the actual situation and the medical economics of the medicine medicine cooperation through the tracing report in the psychiatry domain
栗原正亮1), 山田雅彦2), 下村裕祐2), 公文理沙子2), 桝井章典2), 宇治宏美2), 有山智博3,4), 藤枝正輝5)
The Japanese Society of Psychiatric Pharmacy (suppl): 88-88, 2024.
Japanese Article O3-4. Impression change investigation of the mental disorder by the pharmacy school business training
坂本靖之1), 中島綾夏1), 佐藤康一1), 藤井彩2), 小谷智美1), 田頭尚士1), 藤田秀樹1), 小川喜通1)
The Japanese Society of Psychiatric Pharmacy (suppl): 88-88, 2024.
Japanese Article O3-5. Usefulness examination of the multi-type of job cooperation in our hospital and the in-hospital tracing report
村田峻佑
The Japanese Society of Psychiatric Pharmacy (suppl): 89-89, 2024.
Japanese Article O4-1. The results and effect by the setup of "the insomnia pharmacist outpatient for staff"
奥村知香1), 柏原道志1), 矢部勝茂1), 内山剛2), 大野友久3)
The Japanese Society of Psychiatric Pharmacy (suppl): 89-89, 2024.
Japanese Article O4-3. Prescription analysis for the prescription cascade cancellation in the psychiatry domain
三津石佳奈1), 小田嶋一明2), 中原保裕3), 佐藤悠人1), 小笠原唯1), 櫻井大也1)
The Japanese Society of Psychiatric Pharmacy (suppl): 90-90, 2024.
Japanese Article O4-4. Enforcement of the motivation interview training for the medical person using the online meeting tool and the evaluation
細川智成1,2), 小武和正1), 北川航平3), 芹澤賀子4), 上柳佳子5), 西方雄太郎6), 中島匠海6), 安藤南美6), 中村光男7), 青島周一2,8), 桑原秀徳2,9)
The Japanese Society of Psychiatric Pharmacy (suppl): 91-91, 2024.
Japanese Article O4-5. A case which was tied to the rehospitalization prevention and a prescription review by the home care patient visit drug control instruction of the university hospital psychiatry charge pharmacist
荒木遥菜1), 波多野正和1,2), 蟹江孝樹1,2), 鈴木孝幸1,2), 齋藤竹生3), 山田成樹1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 91-91, 2024.
Japanese Article P-1. Examination of the cognitive function rating system using the psychokinesia function test in patients with schizophrenia
三浦直緒1), 清水侑真2), 竹内一平1,3), 波多野正和1,4), 半谷眞七子1,2), 藤田潔3), 岩田仲生5), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 92-92, 2024.
Japanese Article P-2. Examination of the effectiveness of Lurasidone for patients with schizophrenia with uneasy/depressive symptom
森田絵美里1), 竹内一平1,3), 清水侑真2), 半谷眞七子1,2), 藤田潔3), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 92-92, 2024.
Japanese Article P-3. Examination of the risk factor in the cytopenia of the Clozapine
河原理紗1), 木村伊都紀1), 下山航平1), 花井雄貴3), 田形弘実2), 根本隆洋2), 坂本真紀1), 松本高広1)
The Japanese Society of Psychiatric Pharmacy (suppl): 93-93, 2024.
Japanese Article P-4. Effective and safe evaluation of the Clozapine treatment (from introduction start 18 weeks) in the Yahata public welfare hospital
百岳玲南, 加藤史恵, 園田美樹, 柴田木綿
The Japanese Society of Psychiatric Pharmacy (suppl): 93-93, 2024.
Japanese Article P-5. Effect of lithium for the blood toxicity by the Clozapine with HL-60 cells
加藤朱莉1), 鳥居綾2), 吉見陽1), 野田幸裕1)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2024.
Japanese Article P-6. One case of treatment-resistant schizophrenia that adjustment of the Clozapine blood level by the fluvoxamine increase in quantity was effective
鈴木啓真1,2), 渡部和幸1), 平田一耕1,2), 伊藤清美5), 小松英樹3), 舟越亮寛1,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2024.
Japanese Article P-7. Comparison by the visual measure of the injection site pain of the parenteral injection sustained-release for paliperidone palmitate three months
飛田俊介, 山腰真樹子, 水本唯, 酒井駿
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2024.
Japanese Article P-8. 1 case with suspected drug-related interstitial nephritis by the Clozapine
西川幸輝
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2024.
Japanese Article P-9. Investigation about change of prescription in the amoxapine cancellation and the outcome
山本和幸, 深町明里, 松本早苗, 五味和彦
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2024.
Japanese Article P-10. Fact-finding about the nightmare disorder onset of hospitalization, the outpatient after the use of orexin receptor blocker
新保一1,2), 小川千晶1), 古川真央1), 河野通寿1), 古野毅彦2), 新福正機2), 軍司剛宏1)
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2024.
Japanese Article P-11. Use pulse-taking of the benzodiazepine receptor agonist in the orthopedics ward or the orexin receptor blocker introduction patients
古川真央1), 新保一1), 小川千晶1), 目黒康平2), 森岡秀夫3), 軍司剛宏1)
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2024.
Japanese Article P-12. One case with suspected participation in urinary retention of the orexin receptor blocker
高橋裕1), 板野美和子1), 松岡彩2), 首藤雅美1), 赤田卓志朗2)
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2024.
Japanese Article P-13. The current situation of the psychiatry liaison team approach in medical care in the University of Miyazaki faculty of medicine hospital
保田和哉, 池田龍二
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2024.
Japanese Article P-14. It is ... for proper use of efforts - irritant cathartic to chronic constipation treatment in patients with mental disorder
中村健二, 平茂樹, 土井加代子
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2024.
Japanese Article P-15. 1 case that reduced the psychotropic drug multiple drug prescription of the patients in the general hospital for cancer terminal phase for acute phase
岡崎華歩1), 佐藤一求1), 畝本由貴1), 江草有紀1), 砂取広之1), 別所千枝1), 小野晴久2)
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2024.
Japanese Article P-16. Change to the orexin receptor blockade for patients with myasthenia gravis of the benzodiazepine drugs long-term use
喜田昌記1), 松浦里紗子1), 福岡大延1), 汐見史織1), 長井友子2), 柏原由佳1)
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2024.
Japanese Article P-17. Examination of the relationship between sarcopenia, dynapenia, and medications taken in schizophrenia patients undergoing long-term hospitalization in psychiatric beds
小林聖子1), 堀井裕太2)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2024.
Japanese Article P-18. A case of patients with breast cancer given cancer chemotherapy avoiding drug interactions of the carbamazepine led by a pharmacist in cooperation with other institutions
坪内清貴1), 高林真貴子1), 泉実公子1), 竹本弘樹1), 田淵克則2), 坪本真3), 崔吉道1)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2024.
Japanese Article P-19. A case which we conducted medication counseling based on psychological tests results, and medication adherence improved
嶋村悠実1), 於本崇志1), 朝賀純一1,2), 土方真吾3), 大塚耕太郎3), 工藤賢三1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2024.
Japanese Article P-20. About the utilization to patients information sharing by the instruction joint at the discharge in the psychiatry domain and an at-home visit
上條千恵子
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2024.
Japanese Article P-21. A case of tardive dyskinesia in which oral administration of valbenazine was successfully resumed after desensitization therapy
山本将太1), 稲葉啓通2), 小島悠輔1), 田澤晃太朗1), 阪居伸哉1), 重面雄紀1), 津田真弘1), 村井俊哉2), 寺田智祐1)
The Japanese Society of Psychiatric Pharmacy (suppl): 102-102, 2024.
Japanese Article P-22. It is one patient receiving the Clozapine for patients with integration ataxia emotional disorder under the new coronavirus infection outbreak
石川憲行1), 宮脇知恵子1), 大久保穣2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 102-102, 2024.
Japanese Article P-23. Examination (backward investigation) of the effect that COVID-19 incidence gives to the blood level of the mood stabilizer
高橋裕1), 板野美和子1), 首藤雅美1), 須藤友博2), 赤田卓志朗2)
The Japanese Society of Psychiatric Pharmacy (suppl): 103-103, 2024.
Japanese Article P-24. Examination of the effect that going to hospital distance gives to sustained-release parenteral injection introduction
赤瀬川豊1), 井上雅文2)
The Japanese Society of Psychiatric Pharmacy (suppl): 103-103, 2024.
Japanese Article P-25. Tracing report fact-finding from the family drugstore
加藤剛1), 北田亜美1), 星野雅人1), 宗像彩香1), 澤口真紀1), 土井信幸2)
The Japanese Society of Psychiatric Pharmacy (suppl): 104-104, 2024.
Japanese Article P-26. The effect that a pharmacist in the epilepsy outpatient department gives in patients satisfaction and the office hours of the physician
水村亮介1), 渡邊さつき2), 石川章1), 眞壁秀樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 104-104, 2024.
Japanese Article P-27. The effect that distribution restrictions of biperiden gave in the psychotropic drug prescription of the outpatient
滝澤理貴, 島本翔太, 井上純孝
The Japanese Society of Psychiatric Pharmacy (suppl): 105-105, 2024.
Japanese Article P-28. Investigation about the usefulness of the tardive dyskinesia symptom evaluation sheet in the psychiatry outpatient department
末田有土, 山田雅彦
The Japanese Society of Psychiatric Pharmacy (suppl): 105-105, 2024.
Japanese Article P-29. Personal guidelines fidelity in the EGUIDE project
井手健太1), 稲田健2), 福本健太郎3), 長谷川尚美1), 村岡寛之2), 小高文聰4), 越智紳一郎5), 安田由華1,6), 飯田仁志7), 堀輝7), 大井一高8), 市橋香代9), 川俣安史10), 古郡規雄10), 橋本亮太1)
The Japanese Society of Psychiatric Pharmacy (suppl): 106-106, 2024.
Japanese Article P-30. Examination of the cognitive function rating system using the psychokinesia function test in the use of alcohol disorder patients
冨田夏希1), 清水侑真2), 鈴木香帆1), 宮浦淳一1,3), 森下夏帆3), 水島久美子3), 内田あおい3), 奥田正英3), 水谷浩明3), 半谷眞七子1,2), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 106-106, 2024.
Japanese Article P-31. Evaluation of the in paired performance using the psychokinesia function test by the antihistamine remedy in patients with skin disease
大河内裕矢1), 清水侑真1), 大橋幸輝1), 平沼翔太2), 榎本尚人2), 榊原幹夫2), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 107-107, 2024.
Japanese Article P-32. Transformation of the higher brain function in the proto cadherin 15 (Pcdh15) mutation in the gene mouse and the intracerebral amino acid nerve
加藤拓真1), 高橋礼貴1), 伊藤貴博1), 加納正暉1), 楠本美優1), 吉田樹生1), 森大輔2), 尾崎紀夫2), 吉見陽1,2), 野田幸裕1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 107-107, 2024.
▲